Yamasaki N, Tamura Y, Kaga H, Sato M, et al. A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin. Diabetes Obes Metab 2021;23:1092-1100.
PMID: 33377253